Tag: M.W:100-200

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3405-77-4,5-Methylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

To a solution of the product from step 2 (57 mg, 0.17 mmol) and 5-methylisoxazole-3-carboxylicacid (23 mg, 0.18 mmol) in CH2C12 (2 mL) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (38 mg, 0.20 mmol) and HOBTH2O (2.5 mg, 0.017 mmol) and the solution stirred at RT for 20 h. 5-Methylisoxazole-3-carboxylic acid (23 mg, 0.18 mmol) and 1-ethyl-3-(3-dimethylamino- propyl)carbodiimide hydrochloride (38 mg, 0.20 mmol) were added and the solution stirred at RT for 3 days. Water (2 mL) was added then the aqueous extracted with CH2C12 (2 mL). The combined organicswere passed through a hydrophobic fit and concentrated in vacuo to leave a colourless residue. Flash chromatography (10-45percent EtOAc-cyclohexane) gave a clear gum (62 mg). Freeze-drying from acetonitrile-water (1:1, 3 mL) left a white solid (56 mg). 1H NMR (400 MHz, DMSO-d6) -3:1 ratio rotamers: 1H NMR (400 MHz, CDC13) 7.42 – 7.35 (2H, m), 7.03 (2H, dd, J=8.0, 8.0 Hz), 6.56 (1H, s), 4.47 (1H, d, J=14.3 Hz), 4.21 – 3.91 (3H, m), 2.97 (1H, d, J=4.0 Hz), 2.36 – 2.34 (6H, m), 1.37 – 1.23 (7H,m), 0.70 (3H, s); MS (ESI): [M+H] 453.2., 3405-77-4

As the paragraph descriping shows that 3405-77-4 is playing an increasingly important role.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; GENENTECH, INC.; FAUBER, Benjamin; CRAWFORD, James J.; BRONNER, Sarah M.; BODIL VAN NIEL, Monique; CRIDLAND, Andrew; GANCIA, Emanuela; HURLEY, Christopher; KILLEN, Jonathan; WARD, Stuart; (108 pag.)WO2016/177760; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.131052-47-6,(3,5-Dimethylisoxazol-4-yl)methanamine,as a common compound, the synthetic route is as follows.

A mixture of (3,5-dimethylisoxazol-4-yl)methanamine (70 mg, 0.6 mmol), 4- phenoxycarbonylamino-benzoic acid ethyl ester (150 mg, 0.5 mmol) and TEA (0.2 mL, 1.6 mmol) in MeCN (8 mL) was stirred at 80 C for 1 h and then concentrated. The residue was diluted with DCM (40 mL), washed with aq.HC1 (1 N, 20 mL) and Sat.NaHCO3 (20 mL). The DCM solution was dried over Na2SO4, concentrated and purified by Prep-HPLC (NH3.H20) to give ethyl 4-(3-((3,5- dimethylisoxazol-4-yl)methyl)ureido)benzoate (50 mg, yield: 30%) as a white solid. ?H NIVIR (400 IVIHz, DMSO-d6): oe = 8.85 (s, 1H), 7.82 (d, J= 8.8 Hz, 2H), 7.50 (d, J 8.8 Hz, 2H), 6.64 (t, J 5.6 Hz, 1H), 4.26 (q, J= 7.2 Hz, 2H), 4.06 (d, J= 5.6 Hz, 2H), 2.38 (s, 3H), 2.21 (s, 3H), 1.29 (t, J 7.2 Hz, 3H). MS: m/z 318.0 (M+H).

131052-47-6, The synthetic route of 131052-47-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; GARDELL, Stephen; PINKERTON, Anthony B.; SERGIENKO, Eduard; SESSIONS, Hampton; (428 pag.)WO2018/132372; (2018); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4369-55-5,5-Amino-3-phenylisoxazole,as a common compound, the synthetic route is as follows.

Scheme 42 [0546] A mixture of tert-butyl (lS,2R)-2-(5-bromo-4-cyano-2- fluorophenylamino)cyclohexylcarbamate (165 mg, 0.400 mmol), 5-amino-3-phenylisoxazole (96 mg, 0.600 mmol), sodium phenoxide trihydrate (136 mg, 0.800 mmol), xantphos (30 mg, 0.051 mmol) and Pd2(dba)3 (30 mg, 0.032 mmol) in dioxane (2 mL) was degassed with Ar, then was heated at 170 C for 30 min by microwave. It was concentrated in vacuo. The residue was purified by HPLC to give tert-butyl (lS,2R)-2-(4-cyano-2-fluoro-5-(3- phenylisoxazol-5 -ylamino)phenylamino)cyclohexylcarbamate (40 mg) .

4369-55-5, The synthetic route of 4369-55-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PORTOLA PHARMACEUTICALS, INC.; JIA, Zhaozhong, J.; SONG, Yonghong; XU, Qing; KANE, Brian; BAUER, Shawn, M.; PANDEY, Anjali; WO2012/61418; (2012); A2;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62348-13-4,Isoxazole-5-carbonyl chloride,as a common compound, the synthetic route is as follows.

62348-13-4, EXAMPLE 11 Preparation of 5-chloro-2-(isoxazol-5-yl)-7-[2-(pyridin-2-yl)ethyl]-benzoxazole This is prepared from 2-amino-4-chloro-6-[2-(pyridin-2-yl)ethyl]phenol and isoxazole-5-carbonyl chloride using method A with 1,4-dioxan as solvent to give the intermediate amide (65%). This is cyclised with methanesulphonic acid in toluene at reflux under standard conditions to give the title compound (46%) as a white crystalline solid m.p. 109-112 C. TLC (SiO2, EtOAc:hexanes 1:1, Rf=0.30). Mass spectrum CI (methane) m/z=326 [M+H]+.

62348-13-4 Isoxazole-5-carbonyl chloride 2736707, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; Euro-Celtique, S.A.; US6166041; (2000); A;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

4369-55-5, 5-Amino-3-phenylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 19: l-oxo-N-(3-phenyl-l,2-oxazol-5-yl)-2,3,4,5-tetrahydi[l,4]diazepino[l,2-a]benzimidazole-8-carboxamideA solution of l-oxo-2,3,4,5-tetrahydro-lH-[l,4]diazepino[l,2-a]benzimidazole-8- carboxylc acid (Intermediate B, 71 mg, 0.29 mmol) and Iota,Gamma-carbonyldiimidazole (117 mg, 0.72 mmol) in THF (10 mL) is heated to 60 ¡ãC for 1 h. The solution is cooled to room temperature and 5-methyl-3-aminoisoxazole (191 mg, 1.16 mmol) is added. After 10 min DBU (0.11 mL, 0.72 mmol) is added and the mixture heated at 60 ¡ãC for 16 h. The solvent is evaporated and H20 is added to the residue. The resulting solid is collected by filtration and is purified via preparative HPLC to afford the title compound (17 mg, 12percent).

4369-55-5, As the paragraph descriping shows that 4369-55-5 is playing an increasingly important role.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BOYER, Stephen, James; BURKE, Jennifer; GUO, Xin; KIRRANE JR., Thomas, Martin; SNOW, Roger, John; ZHANG, Yunlong; WO2011/71725; (2011); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

36958-61-9, 5-(Bromomethyl)-3-methylisoxazole is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

STEP A: ethyl 4-bromo-5-methyl-l-((3-methylisoxazol-5-yl)methyl)-lH-pyrazole- 3-carboxylate and ethyl 4-bromo-3-methyl-l-((3-methylisoxazol-5-yl)methyl)-lH-pyrazole- 5-carboxylate and [1124] To a mixture of ethyl 4-bromo-3-methyl-lH-pyrazole-5-carboxylate (0.331 g, 1.420 mmol) in DMF (10 mL) were added CS2CO3 (1.157 g, 3.55 mmol) and 5-(bromomethyl)-3- methylisoxazole (0.5 g, 2.84 mmol). The reaction mixture was stirred at room temperature for 20 hours and then diluted with water. The product was extracted into EtOAc. The organic phase was dried over Na2S04 and concentrated to give the title compounds as a crude mixture that was used without further purification (0.24 g).

36958-61-9, The synthetic route of 36958-61-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; CHERUVALLATH, Zacharia; ERICKSON, Philip; FENG, Jun; KOMANDLA, Mallareddy; LAWSON, John David; MCBRIDE, Christopher; MIURA, Joanne; MURPHY, Sean; TANG, Mingnam; TON-NU, Huong-Thu; WO2013/130855; (2013); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1202769-66-1,2-(5-Methylisoxazol-3-yl)but-3-yn-2-ol,as a common compound, the synthetic route is as follows.

Step 4: Synthesis of 4-[1-(2-aminopyrimidin-4-yl)-2-[[1-(2-hydroxyethyl)azetidin-3-yl]oxy]-1H-1,3-benzodiazol-6-yl]-2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol A mixture of 2-(3-[[1-(2-aminopyrimidin-4-yl)-6-bromo-1H-1,3-benzodiazol-2-yl]oxy]azetidin-1-yl)ethan-1-ol (80 mg, 0.20 mmol), 2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol (160 mg, 1.06 mmol), bis(triphenylphosphine)palladium(II) dichloride (160 mg, 0.23 mmol) and triethylamine (1 mL) in dimethylsulfoxide (2 mL) was stirred under nitrogen for 2 hr at 70 C. The reaction mixture was cooled to room temperature then filtered through a frit filter to remove the catalyst. The filtrate was purified by preparative HPLC to give 7 mg (7%) of 4-[1-(2-aminopyrimidin-4-yl)-2-[[1-(2-hydroxyethyl)azetidin-3-yl]oxy]-1H-1,3-benzodiazol-6-yl]-2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol as a white solid: 1H NMR (400 MHz, DMSO) delta 8.41 (d, J=5.6 Hz, 1H), 8.17 (s, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 7.10 (s, 2H), 7.01 (d, J=5.6 Hz, 1H), 6.45 (s, 1H), 6.37 (s, 1H), 5.37 (t, J=5.2 Hz, 1H), 4.44 (t, J=5.4 Hz, 1H), 3.75 (t, J=7.2 Hz, 2H), 3.41 (t, J=6.0 Hz, 2H), 3.28 (t, J=6.8 Hz, 2H), 2.57 (s, 2H), 2.41 (s, 3H), 1.81 (s, 3H); LC-MS: m/z=+476 (M+H)+., 1202769-66-1

1202769-66-1 2-(5-Methylisoxazol-3-yl)but-3-yn-2-ol 58221759, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; Genentech, Inc.; US2012/214762; (2012); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1121-13-7,4-Nitroisoxazole,as a common compound, the synthetic route is as follows.

To a solution of 4b (200mg, 1.75mmol) in con. HCl (9mL) was added SnCl2.2H2O (1.98g, 8.77mmol). The mixture was stirred at rt for 1.5h, then adjusted by SaLNa2CO3 to pH=8~9 and filtered. The water phase was extracted with EA (30×4) and the combined extract was dried over anhydrous Na2SO4 and filtered. 5OmL of HClZEt2O solution was added to the filtrate and stirred for 30 min then evaporated to dryness to give 4c (125mg, 59%)., 1121-13-7

1121-13-7 4-Nitroisoxazole 11332437, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; XCOVERY, INC.; WO2009/154769; (2009); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

21169-71-1, Isoxazole-5-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example L Isoxazole-5-carboxylic acid [2-(2-o-tolyl-chroman-6-yloxy)-thiazol-5-ylmethyl]-amide To a solution of [2-(2-o-tolyl-chroman-6-yloxy)-thiazol-5-ylmethyl]amine (150 mg, 0.43 mmol) in DMF (2 ml), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (114 mg, 0.60 mmol, 1.4 eq), 1-hydroxy-benzotriazole (81 mg, 0.60 mmol, 1.4 eq) and N-methylmorpholine (107 mg, 1.07 mmol, 2.5 eq) and isoxazole-5-carboxylic acid (72 mg, 0.64 mmol, 1.5 eq) were added. The mixture was stirred for 16 h, then diluted with water, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a diluted aqueous solution of sodium carbonate and brine, dried over sodium sulfate and filtered, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (silica gel, ethyl acetate/methanol gradient). Isoxazole-5-carboxylic acid [2-(2-o-tolyl-chroman-6-yloxy)-thiazol-5-ylmethyl]-amide (112 mg, 59%) was obtained as a white solid., 21169-71-1

As the paragraph descriping shows that 21169-71-1 is playing an increasingly important role.

Reference£º
Patent; SANOFI; CZECHTIZKY, Werngard; WESTON, John; RACKELMANN, Nils; PODESCHWA, Michael; ARNDT, Petra; WIRTH, Klaus; GOEGELEIN, Heinz; RITZELER, Olaf; KRAFT, Volker; BELLEVERGUE, Patrice; MCCORT, Gary; US2013/65859; (2013); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62348-13-4,Isoxazole-5-carbonyl chloride,as a common compound, the synthetic route is as follows.

62348-13-4, Example 91 N-{[1 ,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo[3,4- b]pyridin-5-yl]methyl}-5-isoxazolecarboxamideA solution of Intermediate 16 (75mg) in anhydrous acetonitrile (1.25ml) was treated with isoxazole-5-carbonyl chloride (33mg) and DIPEA (0.044ml) and stirred at room temperature for 24 hours. The solution was diluted with dichloromethane (10ml), washed with dilute aqueous sodium chloride (2 x 7ml) and evaporated in vacuo to give Example 91 as a yellow sold (104mg). LCMS showed MH+ = 399; TREtau = 1 -98min.

The synthetic route of 62348-13-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2007/36733; (2007); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem